Comparative Effectiveness of Rivaroxaban and Warfarin for Stroke Prevention in Multi-morbid Patients With Nonvalvular Atrial Fibrillation
Phase of Trial: Phase IV
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 10 Oct 2019 Status changed from active, no longer recruiting to completed.
- 16 Jul 2019 Planned End Date changed from 31 Jul 2019 to 1 Nov 2019.
- 16 Jul 2019 Planned primary completion date changed from 31 Jul 2019 to 1 Nov 2019.